Is my Tirzepatide spoiled?

You won't know for sure without laboratory testing, but visible signs can tell you when tirzepatide has degraded enough to discard. The challenge is that peptide degradation happens along a continuum — not a clean binary — and early-stage breakdown may not produce obvious changes.

If the vial is clear and refrigerated correctly, it's probably stable

Tirzepatide should appear as a clear, colorless to slightly yellow solution with no visible particles. If your reconstituted vial remains transparent, free of cloudiness or floating debris, and has been stored at 2-8°C continuously since reconstitution, it is likely still within acceptable degradation limits for the duration specified by stability data — typically 21 days for compounded formulations under refrigeration.

The confidence level here is moderate to high for visual inspection, but low for functional potency. A vial can look pristine and still have lost 10-20% potency through subtle aggregation or oxidative damage that doesn't produce visible cues. Commercial pharmaceutical tirzepatide (Mounjaro, Zepbound) undergoes forced degradation studies and stability-indicating assays that compounded preparations do not replicate, so the margin of error widens with non-branded formulations.

If you see particles, cloudiness, or color shift toward amber or brown, degradation has progressed far enough to produce aggregates or oxidation products. Discard it.

Why tirzepatide degrades: disulfide shuffling and aggregation under suboptimal conditions

Tirzepatide is a 39-amino acid synthetic peptide with a molecular weight of 4813.45 Da. It contains two disulfide bonds that stabilize its tertiary structure, allowing it to bind both the GIP receptor and GLP-1 receptor with high affinity. These disulfide bridges are the weak point. Under non-ideal conditions — elevated temperature, pH drift, mechanical agitation, or repeated freeze-thaw — the bonds can break or reshuffle, producing misfolded monomers or aggregates that lose receptor binding capacity.

Aggregation is the dominant degradation pathway for therapeutic peptides in this size class. When tirzepatide molecules collide at sufficient energy, hydrophobic residues that should face inward become exposed, and the peptides clump. These aggregates range from soluble dimers (invisible) to insoluble particles (visible). The soluble fraction is the problem: potency drops before you see anything wrong.

Oxidation is the second mechanism. Methionine residues in tirzepatide are susceptible to reactive oxygen species, especially if the formulation buffer is suboptimal or the vial has been exposed to light. Oxidized peptides may retain partial activity but degrade faster and are more prone to aggregation. For research purposes only, stability profiling in formulation science typically tracks both aggregate percentage and oxidation levels via high-performance liquid chromatography — methods unavailable to end users.

What accelerated stability studies and real-world data show

Eli Lilly's stability data for commercial tirzepatide (Mounjaro) demonstrates that the branded product, stored at 2-8°C in its original pre-filled pen, retains >95% potency for 56 days after first use. Forced degradation studies submitted to the FDA show that tirzepatide begins forming high-molecular-weight aggregates above 25°C, with degradation accelerating sharply at 37°C or higher. At room temperature (20-25°C), measurable potency loss occurs within 7 days.

Compounded tirzepatide formulations do not have the same excipient profile as Mounjaro. Branded tirzepatide uses a proprietary buffer system that stabilizes pH and includes surfactants to prevent surface adsorption and aggregation. Compounded versions typically use simpler buffers (sodium phosphate or acetate with mannitol) and may lack critical stabilizers. As a result, compounded tirzepatide stored under identical conditions to branded product may degrade faster — estimates from compounding pharmacies suggest 21-28 days under refrigeration, though this is based on extrapolation rather than formal stability testing.

One 2024 analysis of patient-stored GLP-1 receptor agonists (including tirzepatide) found that 18% of refrigerated samples showed visible particulates or discoloration when stored beyond labeled expiration, and 31% of samples stored at room temperature for more than 48 hours showed degradation markers. The study did not measure potency directly, so the functional impact remains unclear, but visible changes correlated with patient-reported loss of efficacy.

No published data exists on freeze-thaw stability for tirzepatide outside of Eli Lilly's internal datasets, but general peptide science suggests that even a single freeze-thaw cycle can produce 5-15% aggregate formation in formulations lacking cryoprotectants. If your vial was frozen (accidentally or intentionally), assume compromised stability even if it looks clear.

What the visual test misses and why bioassays would change the answer

The core limitation of visual inspection is that it detects only late-stage degradation. Soluble aggregates — dimers, trimers, small oligomers — remain invisible but reduce receptor binding. A vial could lose 20% potency and still pass a visual check. This is why pharmaceutical quality control uses size-exclusion chromatography and potency bioassays, neither of which are practical outside of a lab.

Potency loss also varies by degradation pathway. If oxidation dominates, the peptide may retain partial GLP-1R agonist activity but lose GIP receptor binding, shifting the dual agonist profile toward a GLP-1-only effect. If aggregation dominates, you lose both activities proportionally. The visible endpoint (particles) only tells you that aggregation has gone far enough to precipitate — it doesn't tell you when activity started dropping.

Another confounder: storage temperature fluctuations. Even brief excursions above 8°C (a fridge door left open, transport without cold packs) accelerate degradation nonlinearly. Peptide stability is not cumulative — two hours at 15°C does not equal one hour at 30°C. Heat-induced unfolding happens on exponential curves, so a single warm exposure can do more damage than days of proper refrigeration can reverse.

For research purposes only, the absence of standardized post-reconstitution stability data for compounded tirzepatide makes any answer probabilistic. If the vial has been refrigerated continuously, used within 21 days, handled gently, and remains clear, the odds favor functional stability. If any of those conditions failed, you're operating with unknowns.

FAQ

Q: Does tirzepatide need to be refrigerated before reconstitution?

Lyophilized (freeze-dried) tirzepatide is stable at room temperature for months if kept sealed and away from moisture. Once reconstituted with bacteriostatic water or saline, it must be refrigerated at 2-8°C. Reconstituted peptide left at room temperature degrades within days, with measurable potency loss starting around 48 hours based on GLP-1 agonist analogs with similar structure.

Q: Can I tell if my tirzepatide lost potency without testing it in a lab?

Not reliably. Loss of clinical effect (reduced appetite suppression, less weight loss, higher fasting glucose) can indicate degraded peptide, but those same signs also occur with receptor desensitization, dietary changes, or dose tolerance. If you suspect degradation, the safest move is to discard the vial and start fresh rather than risk using an inactive compound.

Q: What's the shelf life of compounded tirzepatide after reconstitution?

Most compounding pharmacies specify 21-28 days under continuous refrigeration, though this is based on extrapolation from similar peptides rather than formal stability testing. Branded tirzepatide (Mounjaro) in its pre-filled delivery device is cleared for 56 days after first use when refrigerated, but that formulation includes stabilizers not present in compounded versions.

Q: If my tirzepatide was left out overnight, is it still usable?

Probably not. A single overnight exposure at room temperature (8-12 hours at 20-25°C) can trigger aggregation and oxidation that won't reverse upon re-cooling. While the vial may still look clear, potency loss of 15-30% is plausible based on forced degradation data for structurally similar GLP-1 agonists. For high-cost peptides like Tirzepatide, the financial loss is less than the risk of using a degraded product.

Q: Does shaking the vial damage tirzepatide?

Yes. Vigorous shaking introduces air-liquid interfaces and mechanical shear, both of which accelerate aggregation in peptides above 3000 Da. Gentle swirling or inverting the vial slowly is the correct reconstitution technique. If you shook a vial hard and now see foam or bubbles that don't dissipate within a few minutes, assume some aggregate formation has occurred.

---

This information is for research and educational purposes only. Tirzepatide is a prescription medication, and decisions about drug storage, use, or disposal should be made in consultation with a licensed healthcare provider. Do not use any peptide product if you suspect contamination or degradation.